PharmaLogic announces opening of radiopharmaceutical production facility in New York City
PharmaLogic Holdings Corp., (“PharmaLogic” or “the company”), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, celebrates the opening of its radiopharmaceutical production and research facility in the Bronx, New York. Acquired in 2022, the facility has undergone…
Clarity and PSI kick off SAR-bisPSMA Phase III
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG (“PSI”), a global contract research organisation committed to on-time enrollment…
Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that the first patient has been dosed with its first-in-class lead molecule, satoreotide, targeting extensive stage small…
